BioSpace News Archive

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) being developed for the treatment of metastatic breast cancer and other women’s cancers

Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced that it has completed the previously announced transaction with Topcon Corporation.

Provided positive update on its four TriTAC® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer

Revenue for the Three-Month Period Ended December 31, 2020 Totals $15.4 Million, up 18% Year-over-Year, with Gross Margin of 61.0%, and Lower Operating Expenses.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, provided a business update and financial results for the year ended December 31, 2020.

Study to enroll 60 participants previously vaccinated with mRNA-1273 in Phase 2, to evaluate booster vaccine candidates against the B.1.351 variant first identified in South Africa

Kewaunee Scientific Corporation reported results for its third quarter of fiscal year 2021, ended January 31, 2021.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced that it will present new translational data at the 2021 American Association for Cancer Research Annual Meeting taking place virtually from April 10-15, 2021.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that it will present data in three poster sessions at the upcoming Virtual 2021 American Association for Cancer Research Annual Meeting being held from April 9-14, 2021.

Tumor model data shows potential of CCR4 antagonist to alter immunosuppressive tumor microenvironment to improve CAR T-cell therapy in solid tumors